Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2011

View Archived Issues

Novel oncolytic agent RX-5902 presented

MCT 4 expression is a marker of radiotherapy outcome in oropharyngeal squamous cell carcinoma

LB-100 enhances antitumor activity of combined veliparib/temozolomide treatment in vivo

Upsher-Smith Laboratories details development of extended-release topiramate formulation

Astellas Pharma claims new lysophospholipid LPA1 receptor antagonists

Aflibercept improves overall survival in phase III trial in metastatic colorectal cancer

TRAIL receptor agonist APG-350 potently induces apoptosis in cancer cells

Adeona Pharma completes trial of reaZin in patients with cognitive impairment

Centocor and Medivir patent new series of HCV NS5B inhibitors

Merck & Co. claims new mitogen-activated protein kinase inhibitors for cancer

Merck & Co. patents new positive allosteric modulators of muscarinic acetylcholine M1 receptor

A.P. Pharma meets with FDA to discuss NDA resubmission for APF-530

Rivastach patch is approved in Japan for Alzheimer's-type dementia

XenoPort and FDA agree on SPA for arbaclofen placarbil phase III trial

New ionotropic glutamate receptor agonists presented

FDA grants orphan drug status to active ingredient of Provectus Pharma's PV-10 in HCC

Genta begins tesetaxel trial in Japan in advanced cancer

Glubes approved in Japan to improve postprandial plasma glucose in patients with type 2 diabetes

IQ Therapeutics completes dosing in phase I IQNLF trial

European Commission approves Novartis' Rasilamlo for high blood pressure

Lipacreon approved in Japan as a pancreatic digestive enzyme replacement

FDA committee recommends approval of Victrelis for chronic HCV genotype 1 infection

FDA issues complete response letter regarding NDA for Aricept patch

Tarix Pharma enrolls first patient in phase I TXA-127 trial

Boehringer Ingelheim enrolls first patient in phase III BI-2013 trial in chronic hepatitis C

Baxter receives approval in Japan for inhaled anesthetic Suprane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.